作者: Andreas A. Argyriou , Haralabos P. Kalofonos
DOI: 10.2119/MOLMED.2008.00123
关键词:
摘要: This review critically evaluates current knowledge of molecularly targeted therapies malignant gliomas. Various single-agent therapies, including growth and survival, have been evaluated in clinical trials but failed to demonstrate a significant survival benefit compared with standard treatment regimens. The efficacy multitargeted kinase inhibitors or combinations single-targeted is promising strategy, requires additional evaluation before definitive conclusions can be made. Important areas for further research include the assessment serum tissue biomarkers, elucidation prognostic molecular markers, determination whether mechanism action drug appropriate genetic alterations observed within individual tumors.